ArticleWorld journal of urology2025
Management and recurrence patterns of radiation-induced cystitis with hematuria: a persistent clinical challenge.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diabetes Is an Independent Risk Factor for Radiation-Induced Hematuria After Robotic Stereotactic Body Radiotherapy for Prostate Cancer.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Self-propelled nanozyme motors for targeted therapy of radiation cystitis by disrupting the inflammation-cfDNA vicious cycle.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRadiation-induced cystitis (RIC) with gross hematuria is a challenging complication in patients undergoing pelvic radiotherapy (RT), often resulting in emergency department (ED) visits and hospital admissions. MATERIALS AND
methodsWe retrospectively reviewed records of patients who received pelvic RT and accessed our ED for RIC between 2019 and 2024. Demographic and clinical data were collected. The primary aim was to evaluate ED management, hospitalization rates, in-hospital care and discharge treatments. Moreover, multivariable Cox-regression (MCR) and Poisson regression analyses were used to identify predictors of recurrent ED visits and number of total hospitalizations.
resultsOverall, 61 patients were identified. Median age at first RIC was 75 years, with a median interval of 7 years (IQR: 2-9) from RT to RIC onset. Among these, 54 (89%) received RT for prostate cancer. At first ED presentation, 25 (41%) had a prior history of RIC. Overall, 32 (52%) required hospitalization. At MCR, age (HR: 1.01, p = 0.03) and anticoagulant/antiplatelet use (HR: 1.8, p = 0.01) were significantly associated with recurrence. Similarly, Poisson regression showed that higher age (RR:1.1, p = 0.02), anticoagulant/antiplatelet therapy (RR:1.6, p = 0.008), prior RIC (RR:2.2, p < 0.001) and longer latency from RT to RIC (RR: 1.3, p = 0.04) were significantly associated to increased risk of multiple hospitalizations.
conclusionOlder age, anticoagulant or antiplatelet use, previous RIC, and delayed RIC onset are independent predictors of multiple hospitalizations. These results highlight the long-term impact of RT-related complications in these patients and the need for improved preventive strategies.
Indexed as
Identifiers
41176524What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.